Ovarian Cancer Drugs Market Size, Share & Trends Report

Ovarian Cancer Drugs Market Size, Share & Trends Analysis Report By Therapeutic Class (PARP, PD-L1, Angiogenesis Inhibitors), By Treatment, By End-use, By Region, And Segment Forecasts, 2023 - 2030

Report ID: GVR-2-68038-380-5
Number of Pages: 94
Format: Electronic (PDF)

Historical Range: 2018 - 2021
Industry: Healthcare

Market Segmentation

Ovarian Cancer Drugs Therapeutic Class Outlook (Revenue, USD Million, 2018 - 2030)
- PARP Inhibitors
- Angiogenesis Inhibitors
- PD-L1 Inhibitors
Ovarian Cancer Drugs End-use Outlook (Revenue, USD Million, 2018 - 2030)
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
Ovarian Cancer Drugs Treatment Outlook (Revenue, USD Million, 2018 - 2030)
- Chemotherapy
- Radiation Therapy
- Hormonal Therapy
- Targeted Therapy & Others
Ovarian Cancer Drugs Regional Outlook (Revenue, USD Million, 2018 - 2030)
- North America
  - North America Ovarian Cancer Drugs Market, Therapeutic Class Outlook (Revenue, USD Million, 2018 - 2030)
    - PARP Inhibitors
    - Angiogenesis Inhibitors
    - PD-L1 Inhibitors
  - North America Ovarian Cancer Drugs Market, End-use Outlook (Revenue, USD Million, 2018 - 2030)
    - Hospital Pharmacy
    - Retail Pharmacy
    - Online Pharmacy
  - North America Ovarian Cancer Drugs Market, Treatment Outlook (Revenue, USD Million, 2018 - 2030)
    - Chemotherapy
    - Radiation Therapy
    - Hormonal Therapy
    - Targeted Therapy & Others
  - U.S.
    - U.S. Ovarian Cancer Drugs Market, Therapeutic Class Outlook (Revenue, USD Million, 2018 - 2030)
      - PARP Inhibitors
      - Angiogenesis Inhibitors
      - PD-L1 Inhibitors
    - U.S. Ovarian Cancer Drugs Market, End-use Outlook (Revenue, USD Million, 2018 - 2030)
      - Hospital Pharmacy
      - Retail Pharmacy
      - Online Pharmacy
    - U.S. Ovarian Cancer Drugs Market, Treatment Outlook (Revenue, USD Million, 2018 - 2030)
      - Chemotherapy
      - Radiation Therapy
      - Hormonal Therapy
      - Targeted Therapy & Others
  - Canada
    - Canada Ovarian Cancer Drugs Market, Therapeutic Class Outlook (Revenue, USD Million, 2018 - 2030)
      - PARP Inhibitors
      - Angiogenesis Inhibitors
      - PD-L1 Inhibitors
    - Canada Ovarian Cancer Drugs Market, End-use Outlook (Revenue, USD Million, 2018 - 2030)
      - Hospital Pharmacy
      - Retail Pharmacy
      - Online Pharmacy
    - Canada Ovarian Cancer Drugs Market, Treatment Outlook (Revenue, USD Million, 2018 - 2030)
      - Chemotherapy
      - Radiation Therapy
      - Hormonal Therapy
      - Targeted Therapy & Others
- Europe
  - Europe Ovarian Cancer Drugs Market, Therapeutic Class Outlook (Revenue, USD Million, 2018 - 2030)
    - PARP Inhibitors
    - Angiogenesis Inhibitors
    - PD-L1 Inhibitors
  - Europe Ovarian Cancer Drugs Market, End-use Outlook (Revenue, USD Million, 2018 - 2030)
    - Hospital Pharmacy
    - Retail Pharmacy
    - Online Pharmacy
  - Europe Ovarian Cancer Drugs Market, Treatment Outlook (Revenue, USD Million, 2018 - 2030)
    - Chemotherapy
    - Radiation Therapy
    - Hormonal Therapy
    - Targeted Therapy & Others
  - UK
    - UK Ovarian Cancer Drugs Market, Therapeutic Class Outlook (Revenue, USD Million, 2018 - 2030)
      - PARP Inhibitors
      - Angiogenesis Inhibitors
      - PD-L1 Inhibitors
    - UK Ovarian Cancer Drugs Market, End-use Outlook (Revenue, USD Million, 2018 - 2030)
      - Hospital Pharmacy
      - Retail Pharmacy
      - Online Pharmacy
    - UK Ovarian Cancer Drugs Market, Treatment Outlook (Revenue, USD Million, 2018 - 2030)
      - Chemotherapy
      - Radiation Therapy
      - Hormonal Therapy
      - Targeted Therapy & Others
  - Germany
    - Germany Ovarian Cancer Drugs Market, Therapeutic Class Outlook (Revenue, USD Million, 2018 - 2030)
      - PARP Inhibitors
      - Angiogenesis Inhibitors
      - PD-L1 Inhibitors
    - Germany Ovarian Cancer Drugs Market, End-use Outlook (Revenue, USD Million, 2018 - 2030)
      - Hospital Pharmacy
      - Retail Pharmacy
      - Online Pharmacy
    - Germany Ovarian Cancer Drugs Market, Treatment Outlook (Revenue, USD Million, 2018 - 2030)
      - Chemotherapy
      - Radiation Therapy
      - Hormonal Therapy
      - Targeted Therapy & Others
  - France
    - France Ovarian Cancer Drugs Market, Therapeutic Class Outlook (Revenue, USD Million, 2018 - 2030)
      - PARP Inhibitors
      - Angiogenesis Inhibitors
      - PD-L1 Inhibitors
    - France Ovarian Cancer Drugs Market, End-use Outlook (Revenue, USD Million, 2018 - 2030)
      - Hospital Pharmacy
      - Retail Pharmacy
      - Online Pharmacy
    - France Ovarian Cancer Drugs Market, Treatment Outlook (Revenue, USD Million, 2018 - 2030)
      - Chemotherapy
      - Radiation Therapy
      - Hormonal Therapy
      - Targeted Therapy & Others
  - Italy
    - Italy Ovarian Cancer Drugs Market, Therapeutic Class Outlook (Revenue, USD Million, 2018 - 2030)
      - PARP Inhibitors
      - Angiogenesis Inhibitors
      - PD-L1 Inhibitors
    - Italy Ovarian Cancer Drugs Market, End-use Outlook (Revenue, USD Million, 2018 - 2030)
      - Hospital Pharmacy
      - Retail Pharmacy
      - Online Pharmacy
    - Italy Ovarian Cancer Drugs Market, Treatment Outlook (Revenue, USD Million, 2018 - 2030)
      - Chemotherapy
      - Radiation Therapy
      - Hormonal Therapy
      - Targeted Therapy & Others
  - Spain
    - Spain Ovarian Cancer Drugs Market, Therapeutic Class Outlook (Revenue, USD Million, 2018 - 2030)
      - PARP Inhibitors
      - Angiogenesis Inhibitors
      - PD-L1 Inhibitors
    - Spain Ovarian Cancer Drugs Market, End-use Outlook (Revenue, USD Million, 2018 - 2030)
      - Hospital Pharmacy
      - Retail Pharmacy
      - Online Pharmacy
    - Spain Ovarian Cancer Drugs Market, Treatment Outlook (Revenue, USD Million, 2018 - 2030)
      - Chemotherapy
      - Radiation Therapy
      - Hormonal Therapy
      - Targeted Therapy & Others
  - Sweden
    - Sweden Ovarian Cancer Drugs Market, Therapeutic Class Outlook (Revenue, USD Million, 2018 - 2030)
      - PARP Inhibitors
      - Angiogenesis Inhibitors
      - PD-L1 Inhibitors
    - Sweden Ovarian Cancer Drugs Market, End-use Outlook (Revenue, USD Million, 2018 - 2030)
      - Hospital Pharmacy
      - Retail Pharmacy
      - Online Pharmacy
    - Sweden Ovarian Cancer Drugs Market, Treatment Outlook (Revenue, USD Million, 2018 - 2030)
      - Chemotherapy
      - Radiation Therapy
      - Hormonal Therapy
      - Targeted Therapy & Others
  - Norway
    - Norway Ovarian Cancer Drugs Market, Therapeutic Class Outlook (Revenue, USD Million, 2018 - 2030)
      - PARP Inhibitors
      - Angiogenesis Inhibitors
      - PD-L1 Inhibitors
    - Norway Ovarian Cancer Drugs Market, End-use Outlook (Revenue, USD Million, 2018 - 2030)
      - Hospital Pharmacy
      - Retail Pharmacy
      - Online Pharmacy
    - Norway Ovarian Cancer Drugs Market, Treatment Outlook (Revenue, USD Million, 2018 - 2030)
      - Chemotherapy
      - Radiation Therapy
      - Hormonal Therapy
      - Targeted Therapy & Others
  - Denmark
    - Denmark Ovarian Cancer Drugs Market, Therapeutic Class Outlook (Revenue, USD Million, 2018 - 2030)
      - PARP Inhibitors
      - Angiogenesis Inhibitors
      - PD-L1 Inhibitors
    - Denmark Ovarian Cancer Drugs Market, End-use Outlook (Revenue, USD Million, 2018 - 2030)
      - Hospital Pharmacy
      - Retail Pharmacy
      - Online Pharmacy
    - Denmark Ovarian Cancer Drugs Market, Treatment Outlook (Revenue, USD Million, 2018 - 2030)
      - Chemotherapy
      - Radiation Therapy
      - Hormonal Therapy
      - Targeted Therapy & Others
- Asia Pacific
  - Asia Pacific Ovarian Cancer Drugs Market, Therapeutic Class Outlook (Revenue, USD Million, 2018 - 2030)
    - PARP Inhibitors
    - Angiogenesis Inhibitors
    - PD-L1 Inhibitors
  - Asia Pacific Ovarian Cancer Drugs Market, End-use Outlook (Revenue, USD Million, 2018 - 2030)
    - Hospital Pharmacy
    - Retail Pharmacy
    - Online Pharmacy
  - Asia Pacific Ovarian Cancer Drugs Market, Treatment Outlook (Revenue, USD Million, 2018 - 2030)
    - Chemotherapy
    - Radiation Therapy
    - Hormonal Therapy
    - Targeted Therapy & Others
  - Japan
    - Japan Ovarian Cancer Drugs Market, Therapeutic Class Outlook (Revenue, USD Million, 2018 - 2030)
      - PARP Inhibitors
      - Angiogenesis Inhibitors
      - PD-L1 Inhibitors
    - Japan Ovarian Cancer Drugs Market, End-use Outlook (Revenue, USD Million, 2018 - 2030)
      - Hospital Pharmacy
      - Retail Pharmacy
      - Online Pharmacy
    - Japan Ovarian Cancer Drugs Market, Treatment Outlook (Revenue, USD Million, 2018 - 2030)
      - Chemotherapy
      - Radiation Therapy
      - Hormonal Therapy
      - Targeted Therapy & Others
  - China
    - China Ovarian Cancer Drugs Market, Therapeutic Class Outlook (Revenue, USD Million, 2018 - 2030)
      - PARP Inhibitors
      - Angiogenesis Inhibitors
      - PD-L1 Inhibitors
    - China Ovarian Cancer Drugs Market, End-use Outlook (Revenue, USD Million, 2018 - 2030)
      - Hospital Pharmacy
      - Retail Pharmacy
      - Online Pharmacy
    - China Ovarian Cancer Drugs Market, Treatment Outlook (Revenue, USD Million, 2018 - 2030)
      - Chemotherapy
      - Radiation Therapy
      - Hormonal Therapy
      - Targeted Therapy & Others
  - India
    - India Ovarian Cancer Drugs Market, Therapeutic Class Outlook (Revenue, USD Million, 2018 - 2030)
      - PARP Inhibitors
      - Angiogenesis Inhibitors
      - PD-L1 Inhibitors
    - India Ovarian Cancer Drugs Market, End-use Outlook (Revenue, USD Million, 2018 - 2030)
      - Hospital Pharmacy
      - Retail Pharmacy
      - Online Pharmacy
    - India Ovarian Cancer Drugs Market, Treatment Outlook (Revenue, USD Million, 2018 - 2030)
      - Chemotherapy
      - Radiation Therapy
      - Hormonal Therapy
      - Targeted Therapy & Others
  - Australia
    - Australia Ovarian Cancer Drugs Market, Therapeutic Class Outlook (Revenue, USD Million, 2018 - 2030)
      - PARP Inhibitors
      - Angiogenesis Inhibitors
      - PD-L1 Inhibitors
    - Australia Ovarian Cancer Drugs Market, End-use Outlook (Revenue, USD Million, 2018 - 2030)
      - Hospital Pharmacy
      - Retail Pharmacy
      - Online Pharmacy
    - Australia Ovarian Cancer Drugs Market, Treatment Outlook (Revenue, USD Million, 2018 - 2030)
      - Chemotherapy
      - Radiation Therapy
      - Hormonal Therapy
      - Targeted Therapy & Others
  - Thailand
    - Thailand Ovarian Cancer Drugs Market, Therapeutic Class Outlook (Revenue, USD Million, 2018 - 2030)
      - PARP Inhibitors
      - Angiogenesis Inhibitors
      - PD-L1 Inhibitors
    - Thailand Ovarian Cancer Drugs Market, End-use Outlook (Revenue, USD Million, 2018 - 2030)
      - Hospital Pharmacy
      - Retail Pharmacy
      - Online Pharmacy
    - Thailand Ovarian Cancer Drugs Market, Treatment Outlook (Revenue, USD Million, 2018 - 2030)
      - Chemotherapy
      - Radiation Therapy
      - Hormonal Therapy
      - Targeted Therapy & Others
  - South Korea
    - South Korea Ovarian Cancer Drugs Market, Therapeutic Class Outlook (Revenue, USD Million, 2018 - 2030)
      - PARP Inhibitors
      - Angiogenesis Inhibitors
      - PD-L1 Inhibitors
    - South Korea Ovarian Cancer Drugs Market, End-use Outlook (Revenue, USD Million, 2018 - 2030)
      - Hospital Pharmacy
      - Retail Pharmacy
      - Online Pharmacy
    - South Korea Ovarian Cancer Drugs Market, Treatment Outlook (Revenue, USD Million, 2018 - 2030)
      - Chemotherapy
      - Radiation Therapy
      - Hormonal Therapy
      - Targeted Therapy & Others
- Latin America
  - Latin America Ovarian Cancer Drugs Market, Therapeutic Class Outlook (Revenue, USD Million, 2018 - 2030)
    - PARP Inhibitors
    - Angiogenesis Inhibitors
    - PD-L1 Inhibitors
  - Latin America Ovarian Cancer Drugs Market, End-use Outlook (Revenue, USD Million, 2018 - 2030)
    - Hospital Pharmacy
    - Retail Pharmacy
    - Online Pharmacy
  - Latin America Ovarian Cancer Drugs Market, Treatment Outlook (Revenue, USD Million, 2018 - 2030)
    - Chemotherapy
    - Radiation Therapy
    - Hormonal Therapy
    - Targeted Therapy & Others
  - Brazil
    - Brazil Ovarian Cancer Drugs Market, Therapeutic Class Outlook (Revenue, USD Million, 2018 - 2030)
      - PARP Inhibitors
      - Angiogenesis Inhibitors
      - PD-L1 Inhibitors
    - Brazil Ovarian Cancer Drugs Market, End-use Outlook (Revenue, USD Million, 2018 - 2030)
      - Hospital Pharmacy
      - Retail Pharmacy
      - Online Pharmacy
    - Brazil Ovarian Cancer Drugs Market, Treatment Outlook (Revenue, USD Million, 2018 - 2030)
      - Chemotherapy
      - Radiation Therapy
      - Hormonal Therapy
      - Targeted Therapy & Others
  - Mexico
    - Mexico Ovarian Cancer Drugs Market, Therapeutic Class Outlook (Revenue, USD Million, 2018 - 2030)
      - PARP Inhibitors
      - Angiogenesis Inhibitors
      - PD-L1 Inhibitors
    - Mexico Ovarian Cancer Drugs Market, End-use Outlook (Revenue, USD Million, 2018 - 2030)
      - Hospital Pharmacy
      - Retail Pharmacy
      - Online Pharmacy
    - Mexico Ovarian Cancer Drugs Market, Treatment Outlook (Revenue, USD Million, 2018 - 2030)
      - Chemotherapy
      - Radiation Therapy
      - Hormonal Therapy
      - Targeted Therapy & Others
  - Argentina
    - Argentina Ovarian Cancer Drugs Market, Therapeutic Class Outlook (Revenue, USD Million, 2018 - 2030)
      - PARP Inhibitors
      - Angiogenesis Inhibitors
      - PD-L1 Inhibitors
    - Argentina Ovarian Cancer Drugs Market, End-use Outlook (Revenue, USD Million, 2018 - 2030)
      - Hospital Pharmacy
      - Retail Pharmacy
      - Online Pharmacy
    - Argentina Ovarian Cancer Drugs Market, Treatment Outlook (Revenue, USD Million, 2018 - 2030)
      - Chemotherapy
      - Radiation Therapy
      - Hormonal Therapy
      - Targeted Therapy & Others
- Middle East and Africa
  - MEA Ovarian Cancer Drugs Market, Therapeutic Class Outlook (Revenue, USD Million, 2018 - 2030)
    - PARP Inhibitors
    - Angiogenesis Inhibitors
    - PD-L1 Inhibitors
  - MEA Ovarian Cancer Drugs Market, End-use Outlook (Revenue, USD Million, 2018 - 2030)
    - Hospital Pharmacy
    - Retail Pharmacy
    - Online Pharmacy
  - MEA Ovarian Cancer Drugs Market, Treatment Outlook (Revenue, USD Million, 2018 - 2030)
    - Chemotherapy
    - Radiation Therapy
    - Hormonal Therapy
    - Targeted Therapy & Others
  - Saudi Arabia
    - Saudi Arabia Ovarian Cancer Drugs Market, Therapeutic Class Outlook (Revenue, USD Million, 2018 - 2030)
      - PARP Inhibitors
      - Angiogenesis Inhibitors
      - PD-L1 Inhibitors
    - Saudi Arabia Ovarian Cancer Drugs Market, End-use Outlook (Revenue, USD Million, 2018 - 2030)
      - Hospital Pharmacy
      - Retail Pharmacy
      - Online Pharmacy
    - Saudi Arabia Ovarian Cancer Drugs Market, Treatment Outlook (Revenue, USD Million, 2018 - 2030)
      - Chemotherapy
      - Radiation Therapy
      - Hormonal Therapy
      - Targeted Therapy & Others
  - South Africa
    - South Africa Ovarian Cancer Drugs Market, Therapeutic Class Outlook (Revenue, USD Million, 2018 - 2030)
      - PARP Inhibitors
      - Angiogenesis Inhibitors
      - PD-L1 Inhibitors
    - South Africa Ovarian Cancer Drugs Market, End-use Outlook (Revenue, USD Million, 2018 - 2030)
      - Hospital Pharmacy
      - Retail Pharmacy
      - Online Pharmacy
    - South Africa Ovarian Cancer Drugs Market, Treatment Outlook (Revenue, USD Million, 2018 - 2030)
      - Chemotherapy
      - Radiation Therapy
      - Hormonal Therapy
      - Targeted Therapy & Others
  - UAE
    - UAE Ovarian Cancer Drugs Market, Therapeutic Class Outlook (Revenue, USD Million, 2018 - 2030)
      - PARP Inhibitors
      - Angiogenesis Inhibitors
      - PD-L1 Inhibitors
    - UAE Ovarian Cancer Drugs Market, End-use Outlook (Revenue, USD Million, 2018 - 2030)
      - Hospital Pharmacy
      - Retail Pharmacy
      - Online Pharmacy
    - UAE Ovarian Cancer Drugs Market, Treatment Outlook (Revenue, USD Million, 2018 - 2030)
      - Chemotherapy
      - Radiation Therapy
      - Hormonal Therapy
      - Targeted Therapy & Others
  - Kuwait
    - Kuwait Ovarian Cancer Drugs Market, Therapeutic Class Outlook (Revenue, USD Million, 2018 - 2030)
      - PARP Inhibitors
      - Angiogenesis Inhibitors
      - PD-L1 Inhibitors
    - Kuwait Ovarian Cancer Drugs Market, End-use Outlook (Revenue, USD Million, 2018 - 2030)
      - Hospital Pharmacy
      - Retail Pharmacy
      - Online Pharmacy
    - Kuwait Ovarian Cancer Drugs Market, Treatment Outlook (Revenue, USD Million, 2018 - 2030)
      - Chemotherapy
      - Radiation Therapy
      - Hormonal Therapy
      - Targeted Therapy & Others

Report content

Qualitative Analysis

Industry overview
Industry trends
Market drivers and restraints
Market size
Growth prospects
Porter’s analysis
PESTEL analysis
Key market opportunities prioritized
Competitive landscape
- Company overview
- Financial performance
- Product benchmarking
- Latest strategic developments

Quantitative Analysis

Market size, estimates, and forecast from 2018 to 2030
Market estimates and forecast for product segments up to 2030
Regional market size and forecast for product segments up to 2030
Market estimates and forecast for application segments up to 2030
Regional market size and forecast for application segments up to 2030
Company financial performance

GET A FREE SAMPLE

This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself.

Or view our licence options:

NEED A CUSTOM REPORT?

We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities.

ESOMAR certified & member

ISO Certified

We are GDPR and CCPA compliant! Your transaction & personal information is safe and secure. For more details, please read our privacy policy.